In a report released today, Luke Sergott from Barclays maintained a Hold rating on Certara (CERT – Research Report), with a price target of $18.00. The company’s shares closed yesterday at $17.66.
Sergott covers the Healthcare sector, focusing on stocks such as Illumina, Icon, and Pacific Biosciences. According to TipRanks, Sergott has an average return of -3.3% and a 43.13% success rate on recommended stocks.
Certara has an analyst consensus of Hold, with a price target consensus of $19.10.
Based on Certara’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $88.01 million and a GAAP net loss of $12.46 million. In comparison, last year the company earned a revenue of $86.63 million and had a net profit of $9.17 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Certara (CERT) Company Description:
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
Read More on CERT:
